TRAW Form 4: Director John Leaman awarded 12,770 options

Rhea-AI Filing Summary

Traws Pharma, Inc. (TRAW) reported an equity compensation grant to one of its directors, John Leaman. On 11/21/2025, he was granted a stock option to purchase 12,770 shares of Traws Pharma common stock at an exercise price of $2.31 per share. The option is held directly and expires on 11/21/2035.

The option vests over three years from the grant date, with 33% vesting on the first anniversary, 33% on the second anniversary, and the remaining 34% on the third anniversary. Following this grant, John Leaman beneficially owns 12,770 derivative securities in the form of these stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leaman John Harold

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTON PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.31	11/21/2025		A		12,770		(1)	11/21/2035	Common Stock	12,770	$0	12,770	D

Explanation of Responses:

1. These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

	/s/ John Leaman	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Traws Pharma (TRAW) report in this Form 4 filing?

Traws Pharma reported that director John Leaman received a grant of stock options for 12,770 shares of common stock on 11/21/2025.

What are the key terms of John Leamans stock options in Traws Pharma (TRAW)?

The options allow John Leaman to buy 12,770 shares of Traws Pharma common stock at an exercise price of $2.31 per share, expiring on 11/21/2035.

How do the Traws Pharma (TRAW) stock options granted to John Leaman vest?

The options vest over three years from the grant date: 33% on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary.

What is John Leamans relationship to Traws Pharma (TRAW)?

John Leaman is a director of Traws Pharma, Inc., as indicated in the filing.

How many derivative securities does John Leaman beneficially own in Traws Pharma (TRAW) after this grant?

After this grant, John Leaman beneficially owns 12,770 derivative securities, all in the form of these stock options held directly.

Is the Traws Pharma (TRAW) stock option grant to John Leaman a direct or indirect holding?

The Form 4 indicates that the 12,770 stock options are held with direct (D) ownership by John Leaman.